Loading
A phase 3 trial of Epcoritamab, Prednisone, Rituximab in follicular lymphoma, run by Genmab, active and no longer recruiting.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma is a phase 3 interventional study registered as NCT06191744 by Genmab, with 1095 participants enrolled, started 2024-02-05 and due to reach its primary completion in 2037-11. Interventions recorded: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Vincristine, Rituximab.
Shares Epcoritamab, Genmab, Lenalidomide, Prednisone.
Shares Genmab, Lenalidomide, Prednisone, Vincristine.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/